Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 587-599 , August 2008

Vitamin D and breast cancer risk

  • Kay W. Colston, PhD (Reader in Clinical Biochemistry and Metabolism)

      Affiliations

    • Corresponding Author InformationTel.: +44 20 8725 4792.

References 

  1. Norman AW, Roth J, Orci L. The vitamin D endocrine system: steroid metabolism, hormone receptors and biological response (calcium binding proteins). Endocrine Reviews. 1982;3:331–366
  2. Colston K, Hirst M, Feldman D. Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology. 1980;107:1916–1922
  3. Stumpf WE, Sar M, Reid FA, et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;20:1188–1190
  4. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981;108:1083–1086
  5. Abe E, Miyaura C, Sakagami H, et al. Differenctiation of mouse myeloid leukaemia cells induced by 1alpha,25-dihydroxyvitamin D3. Proceedings of the National Academy of Sciences of the United States of America. 1981;78:4990–4994
  6. Campbell MJ, Gombart AF, Kwok SH, et al. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 2000;19:5091–5097
  7. Campbell MJ, Elstner E, Holden S, et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadheren. Journal of Molecular Endocrinology. 1997;19:15–27
  8. Yang E, Burnstein KI. Vitamin D inhibits G1 to S progression in LNCaP human prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization in the cytoplasm. The Journal of Biological Chemistry. 2003;278:46862–46868
  9. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Research. 1999;59:4848–4856
  10. Banwell CM, MacCartney DP, Guy M, et al. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signalling in breast cancer cells. Clinical Cancer Research. 2006;12:2004–2013
  11. Zinser GM, Welsh J. Effect of vitamin D3 receptor ablation on murine mammary gland development and tumorigenesis. The Journal of Steroid Biochemistry and Molecular Biology. 2004;89–90:433–436
  12. Zinser GM, Welsh J. Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Molecular Endocrinology. 2004;18:2208–2223
  13. Colston KW, Mork Hansen C. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocrine-Related Cancer. 2001;9:45–59
  14. Xue L, Lipkin M, Newmark H, et al. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. Journal of the National Cancer Institute. 1999;91:176–181
  15. Jacobson EA, James KA, Newmark HL, et al. Effects of dietary calcium and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Research. 1989;49:2898–2904
  16. Grant WB. An ecological study of dietary and solar ultra violet B links to breast carcinoma mortality rates. Cancer. 2002;94:272–281
  17. John EM, Schwarttz GG, Dreon DM, et al. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiology Biomarkers & Prevention. 1999;8:399–406
  18. Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiology Biomarkers & Prevention. 2006;15:1427–1437
  19. Shin MH, Holmes MD, Hankinson SE, et al. Intake of dairy products, calcium and vitamin D and risk of breast cancer. Journal of the National Cancer Institute. 2002;94:1301–1311
  20. Apperley FL. The relation of solar radiation to cancer mortality in North America. Cancer Research. 1941;1:191–195
  21. Garland FC, Garland CF, Gorham ED, et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Preventive Medicine. 1990;19:614–622
  22. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. International Journal of Epidemiology. 1990;19:820–824
  23. Adams JS, Clemens TL, Parrish JA, et al. Vitamin D synthesis and metabolism after ultraviolet irradiation of normal and vitamin D-deficient subjects. The New England Journal of Medicine. 1982;306:722–725
  24. Janowsky EC, Lester GE, Weinberg CR, et al. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutrition. 1999;2:283–291
  25. Hiatt R, Krieger B, Lobaugh B, et al. Prediagnostic serum vitamin D and breast cancer. Journal of the National Cancer Institute. 1998;90:461–463
  26. Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2005;14:1991–1997
  27. Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxyvitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. European Journal of Cancer. 2005;41:1164–1169
  28. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. The Journal of Steroid Biochemistry and Molecular Biology. 2007;103:708–711
  29. Berger U, McClelland RA, Wilson P, et al. Immunocytochemical detection of oestrogen receptor, progesterone receptor and 1,25-dihydroxyvitamin D receptor in breast cancer and relation to prognosis. Cancer Research. 1991;51:239–244
  30. Arai H, Miyamoto K, Taketani Y, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. Journal of Bone and Mineral Research. 1997;12:915–921
  31. Ingles SA, Haile RW, Henderson BE, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiology Biomarkers & Prevention. 1997;6:93–98
  32. Chen WY, Bertone-Johnson ER, Hunter DJ, et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiology Biomarkers & Prevention. 2005;14:2335–2339
  33. Bretherton-Watt D, Given-Wilson R, Mansi JL, et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. British Journal of Cancer. 2001;85:171–175
  34. Guy M, Lowe LC, Bretherton-Watt D, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clinical Cancer Research. 2004;10:5472–5481
  35. Ingles SA, Garcia DG, Wang W, et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes & Control. 2000;11:25–30
  36. Curran JE, Vaughan T, Lea RA, et al. Association of a vitamin D receptor polymorphism with sporadic breast cancer development. International Journal of Cancer. 1999;83:723–726
  37. Trabert B, Malone KE, Daling JR, et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case control study of Caucasian and African-American women. Breast Cancer Research. 2007;9:R84
  38. VandeVord PJ, Wooley PH, Darga LL, et al. Genetic determinants of bone mass do not relate with breast cancer risk in US white and African-American women. Breast Cancer Research and Treatment. 2006;100:103–107
  39. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene polymorphisms, diet and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Research. 2007;9:R9
  40. Ruggiero M, Pacini S, Aterini S, et al. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncology Research. 1998;10:43–46
  41. Lundin AC, Soderkvist P, Eriksson B, et al. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Research. 1999;59:2332–2334
  42. Townsend K, Evans KN, Campbell MJ, et al. Biological actions of extra-renal 25-hydroxvitamin D-1a-hydroxylase and implications for chemoprevention and treatment. The Journal of Steroid Biochemistry and Molecular Biology. 2005;97:103–109
  43. Alberton DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Genetics. 2000;25:144–146
  44. Colston KW, Lowe LC, Mansi JL, Campbell MJ. Vitamin D and breast cancer risk. Anticancer Research. 2006;26:2573–2580
  45. Mezzetti G, Barbiroli B, Oka T. 1,25-Dihydroxycholecalciferol receptor regulation in hormonally induced differentiation of mouse mammary gland in culture. Endocrinology. 1987;120:2488–2493
  46. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites and risk of prostate cancer in United States physicians. Cancer Epidemiology Biomarkers & Prevention. 1998;7:385–390
  47. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. The American Journal of Clinical Nutrition. 2004;80(Suppl):1678S–1688S
  48. Garabedian M, Vainsel M, Mallet E, et al. Circulating vitamin D metabolite concentrations in children with nutritional rickets. The Journal of Pediatrics. 1983;103:381–386
  49. Gregory J, Lowe S, Bates CJ, et al. National diet and nutrition survey: young people aged 4 to18 years. London: The Stationery Office; 2000;
  50. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. The American Journal of Clinical Nutrition. 2004;80(Suppl):1706S–1709S
  51. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. Journal of the American College of Nutrition. 2003;22:142–146
  52. Department of Health . Nutrition and bone health with particular reference to calcium and vitamin D. 49. London: The stationery office; 1998;
  53. Expert Group on Vitamins and Minerals . Safe upper levels for vitamins and minerals. London, United Kingdom: Food Standards Agency; 2003;
  54. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's health study. Cancer Causes & Control. 2007;18:775–782
  55. Hathcock JN, Shao A, Veith R, et al. Risk assessment for vitamin D. The American Journal of Clinical Nutrition. 2007;85:6–18

PII: S1521-690X(08)00088-2

doi: 10.1016/j.beem.2008.08.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 587-599 , August 2008

Article Tools

* Image Usage & Resolution